Now showing items 1-20 of 25

    • Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. 

      Rafii, S; Gourley, C; Kumar, R; Geuna, E; Ern Ang, J; Rye, T; Chen, L-M; Shapira-Frommer, R; Friedlander, M; Matulonis, U; De Greve, J; Oza, AM; Banerjee, S; Molife, LR; Gore, ME; Kaye, SB; Yap, TA (2017-07-18)
      BACKGROUND: The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in ...
    • Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. 

      George, A; Kristeleit, R; Rafii, S; Michie, CO; Bowen, R; Michalarea, V; van Hagen, T; Wong, M; Rallis, G; Molife, LR; Lopez, J; Banerji, U; Banerjee, SN; Gore, ME; de Bono, JS; Kaye, SB; Yap, TA (2017-05)
      Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug ...
    • Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. 

      Vergote, I; Banerjee, S; Gerdes, A-M; van Asperen, C; Marth, C; Vaz, F; Ray-Coquard, I; Stoppa-Lyonnet, D; Gonzalez-Martin, A; Sehouli, J; Colombo, N (2016-12)
      Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now ...
    • Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. 

      George, A; Kaye, S; Banerjee, S (2017-05)
      The treatment of patients with ovarian cancer is rapidly changing following the success of poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP inhibitor to be approved by the EMA ...
    • Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. 

      Yang, Y; Wu, L; Shu, X; Lu, Y; Shu, X-O; Cai, Q; Beeghly-Fadiel, A; Li, B; Ye, F; Berchuck, A; Anton-Culver, H; Banerjee, S; Benitez, J; Bjørge, L; Brenton, JD; Butzow, R; Campbell, IG; Chang-Claude, J; Chen, K; Cook, LS; Cramer, DW; deFazio, A; Dennis, J; Doherty, JA; Dörk, T; Eccles, DM; Edwards, DV; Fasching, PA; Fortner, RT; Gayther, SA; Giles, GG; Glasspool, RM; Goode, EL; Goodman, MT; Gronwald, J; Harris, HR; Heitz, F; Hildebrandt, MA; Høgdall, E; Høgdall, CK; Huntsman, DG; Kar, SP; Karlan, BY; Kelemen, LE; Kiemeney, LA; Kjaer, SK; Koushik, A; Lambrechts, D; Le, ND; Levine, DA; Massuger, LF; Matsuo, K; May, T; McNeish, IA; Menon, U; Modugno, F; Monteiro, AN; Moorman, PG; Moysich, KB; Ness, RB; Nevanlinna, H; Olsson, H; Onland-Moret, NC; Park, SK; Paul, J; Pearce, CL; Pejovic, T; Phelan, CM; Pike, MC; Ramus, SJ; Riboli, E; Rodriguez-Antona, C; Romieu, I; Sandler, DP; Schildkraut, JM; Setiawan, VW; Shan, K; Siddiqui, N; Sieh, W; Stampfer, MJ; Sutphen, R; Swerdlow, AJ; Szafron, LM; Teo, SH; Tworoger, SS; Tyrer, JP; Webb, PM; Wentzensen, N; White, E; Willett, WC; Wolk, A; Woo, YL; Wu, AH; Yan, L; Yannoukakos, D; Chenevix-Trench, G; Sellers, TA; Pharoah, PDP; Zheng, W; Long, J (2019-02-01)
      : DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian cancer (EOC) remains ...
    • Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. 

      Capoluongo, E; Ellison, G; López-Guerrero, JA; Penault-Llorca, F; Ligtenberg, MJL; Banerjee, S; Singer, C; Friedman, E; Markiefka, B; Schirmacher, P; Büttner, R; van Asperen, CJ; Ray-Coquard, I; Endris, V; Kamel-Reid, S; Percival, N; Bryce, J; Röthlisberger, B; Soong, R; de Castro, DG (2017-06)
      The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 ...
    • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 

      Phelan, CM; Kuchenbaecker, KB; Tyrer, JP; Kar, SP; Lawrenson, K; Winham, SJ; Dennis, J; Pirie, A; Riggan, MJ; Chornokur, G; Earp, MA; Lyra, PC; Lee, JM; Coetzee, S; Beesley, J; McGuffog, L; Soucy, P; Dicks, E; Lee, A; Barrowdale, D; Lecarpentier, J; Leslie, G; Aalfs, CM; Aben, KKH; Adams, M; Adlard, J; Andrulis, IL; Anton-Culver, H; Antonenkova, N; AOCS study group; Aravantinos, G; Arnold, N; Arun, BK; Arver, B; Azzollini, J; Balmaña, J; Banerjee, SN; Barjhoux, L; Barkardottir, RB; Bean, Y; Beckmann, MW; Beeghly-Fadiel, A; Benitez, J; Bermisheva, M; Bernardini, MQ; Birrer, MJ; Bjorge, L; Black, A; Blankstein, K; Blok, MJ; Bodelon, C; Bogdanova, N; Bojesen, A; Bonanni, B; Borg, Å; Bradbury, AR; Brenton, JD; Brewer, C; Brinton, L; Broberg, P; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Buecher, B; Butzow, R; Buys, SS; Caldes, T; Caligo, MA; Campbell, I; Cannioto, R; Carney, ME; Cescon, T; Chan, SB; Chang-Claude, J; Chanock, S; Chen, XQ; Chiew, Y-E; Chiquette, J; Chung, WK; Claes, KBM; Conner, T; Cook, LS; Cook, J; Cramer, DW; Cunningham, JM; D'Aloisio, AA; Daly, MB; Damiola, F; Damirovna, SD; Dansonka-Mieszkowska, A; Dao, F; Davidson, R; DeFazio, A; Delnatte, C; Doheny, KF; Diez, O; Ding, YC; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Dossus, L; Duran, M; Dürst, M; Dworniczak, B; Eccles, D; Edwards, T; Eeles, R; Eilber, U; Ejlertsen, B; Ekici, AB; Ellis, S; Elvira, M; EMBRACE Study; Eng, KH; Engel, C; Evans, DG; Fasching, PA; Ferguson, S; Ferrer, SF; Flanagan, JM; Fogarty, ZC; Fortner, RT; Fostira, F; Foulkes, WD; Fountzilas, G; Fridley, BL; Friebel, TM; Friedman, E; Frost, D; Ganz, PA; Garber, J; García, MJ; Garcia-Barberan, V; Gehrig, A; GEMO Study Collaborators; Gentry-Maharaj, A; Gerdes, A-M; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goldgar, DE; Goranova, T; Gore, M; Greene, MH; Gronwald, J; Gruber, S; Hahnen, E; Haiman, CA; Håkansson, N; Hamann, U; Hansen, TVO; Harrington, PA; Harris, HR; Hauke, J; HEBON Study; Hein, A; Henderson, A; Hildebrandt, MAT; Hillemanns, P; Hodgson, S; Høgdall, CK; Høgdall, E; Hogervorst, FBL; Holland, H; Hooning, MJ; Hosking, K; Huang, R-Y; Hulick, PJ; Hung, J; Hunter, DJ; Huntsman, DG; Huzarski, T; Imyanitov, EN; Isaacs, C; Iversen, ES; Izatt, L; Izquierdo, A; Jakubowska, A; James, P; Janavicius, R; Jernetz, M; Jensen, A; Jensen, UB; John, EM; Johnatty, S; Jones, ME; Kannisto, P; Karlan, BY; Karnezis, A; Kast, K; KConFab Investigators; Kennedy, CJ; Khusnutdinova, E; Kiemeney, LA; Kiiski, JI; Kim, S-W; Kjaer, SK; Köbel, M; Kopperud, RK; Kruse, TA; Kupryjanczyk, J; Kwong, A; Laitman, Y; Lambrechts, D; Larrañaga, N; Larson, MC; Lazaro, C; Le, ND; Le Marchand, L; Lee, JW; Lele, SB; Leminen, A; Leroux, D; Lester, J; Lesueur, F; Levine, DA; Liang, D; Liebrich, C; Lilyquist, J; Lipworth, L; Lissowska, J; Lu, KH; Lubinński, J; Luccarini, C; Lundvall, L; Mai, PL; Mendoza-Fandiño, G; Manoukian, S; Massuger, LFAG; May, T; Mazoyer, S; McAlpine, JN; McGuire, V; McLaughlin, JR; McNeish, I; Meijers-Heijboer, H; Meindl, A; Menon, U; Mensenkamp, AR; Merritt, MA; Milne, RL; Mitchell, G; Modugno, F; Moes-Sosnowska, J; Moffitt, M; Montagna, M; Moysich, KB; Mulligan, AM; Musinsky, J; Nathanson, KL; Nedergaard, L; Ness, RB; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Nussbaum, RL; Odunsi, K; Olah, E; Olopade, OI; Olsson, H; Olswold, C; O'Malley, DM; Ong, K-R; Onland-Moret, NC; OPAL study group; Orr, N; Orsulic, S; Osorio, A; Palli, D; Papi, L; Park-Simon, T-W; Paul, J; Pearce, CL; Pedersen, IS; Peeters, PHM; Peissel, B; Peixoto, A; Pejovic, T; Pelttari, LM; Permuth, JB; Peterlongo, P; Pezzani, L; Pfeiler, G; Phillips, K-A; Piedmonte, M; Pike, MC; Piskorz, AM; Poblete, SR; Pocza, T; Poole, EM; Poppe, B; Porteous, ME; Prieur, F; Prokofyeva, D; Pugh, E; Pujana, MA; Pujol, P; Radice, P; Rantala, J; Rappaport-Fuerhauser, C; Rennert, G; Rhiem, K; Rice, P; Richardson, A; Robson, M; Rodriguez, GC; Rodríguez-Antona, C; Romm, J; Rookus, MA; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, IB; Salvesen, HB; Sandler, DP; Schoemaker, MJ; Senter, L; Setiawan, VW; Severi, G; Sharma, P; Shelford, T; Siddiqui, N; Side, LE; Sieh, W; Singer, CF; Sobol, H; Song, H; Southey, MC; Spurdle, AB; Stadler, Z; Steinemann, D; Stoppa-Lyonnet, D; Sucheston-Campbell, LE; Sukiennicki, G; Sutphen, R; Sutter, C; Swerdlow, AJ; Szabo, CI; Szafron, L; Tan, YY; Taylor, JA; Tea, M-K; Teixeira, MR; Teo, S-H; Terry, KL; Thompson, PJ; Thomsen, LCV; Thull, DL; Tihomirova, L; Tinker, AV; Tischkowitz, M; Tognazzo, S; Toland, AE; Tone, A; Trabert, B; Travis, RC; Trichopoulou, A; Tung, N; Tworoger, SS; van Altena, AM; Van Den Berg, D; van der Hout, AH; van der Luijt, RB; Van Heetvelde, M; Van Nieuwenhuysen, E; van Rensburg, EJ; Vanderstichele, A; Varon-Mateeva, R; Vega, A; Edwards, DV; Vergote, I; Vierkant, RA; Vijai, J; Vratimos, A; Walker, L; Walsh, C; Wand, D; Wang-Gohrke, S; Wappenschmidt, B; Webb, PM; Weinberg, CR; Weitzel, JN; Wentzensen, N; Whittemore, AS; Wijnen, JT; Wilkens, LR; Wolk, A; Woo, M; Wu, X; Wu, AH; Yang, H; Yannoukakos, D; Ziogas, A; Zorn, KK; Narod, SA; Easton, DF; Amos, CI; Schildkraut, JM; Ramus, SJ; Ottini, L; Goodman, MT; Park, SK; Kelemen, LE; Risch, HA; Thomassen, M; Offit, K; Simard, J; Schmutzler, RK; Hazelett, D; Monteiro, AN; Couch, FJ; Berchuck, A; Chenevix-Trench, G; Goode, EL; Sellers, TA; Gayther, SA; Antoniou, AC; Pharoah, PDP (2017-05)
      To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified ...
    • The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. 

      McLachlan, J; Boussios, S; Okines, A; Glaessgen, D; Bodlar, S; Kalaitzaki, R; Taylor, A; Lalondrelle, S; Gore, M; Kaye, S; Banerjee, S (2017-03)
      AIMS: Despite recent advances in the primary and secondary prevention of cervical cancer, a significant number of women present with or develop metastatic disease. There is currently no consensus on the standard of care ...
    • Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. 

      George, A; Riddell, D; Seal, S; Talukdar, S; Mahamdallie, S; Ruark, E; Cloke, V; Slade, I; Kemp, Z; Gore, M; Strydom, A; Banerjee, S; Hanson, H; Rahman, N (2016-01)
      Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing ...
    • Improving outcomes for older women with gynaecological malignancies. 

      Dumas, L; Ring, A; Butler, J; Kalsi, T; Harari, D; Banerjee, S (2016-08-29)
      The incidence of most gynaecological malignancies rises significantly with increasing age. With an ageing population, the proportion of women over the age of 65 with cancer is expected to rise substantially over the next ...
    • Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. 

      Dolly, SO; Migali, C; Tunariu, N; Della-Pepa, C; Khakoo, S; Hazell, S; de Bono, JS; Kaye, SB; Banerjee, S (2017)
      Peritoneal mesothelioma (MPeM) is a scarce abdominal-pelvic malignancy that presents with non-specific features and exhibits a wide clinical spectrum from indolent to aggressive disease. Due to it being a rare entity, there ...
    • The integration of BRCA testing into oncology clinics. 

      Percival, N; George, A; Gyertson, J; Hamill, M; Fernandes, A; Davies, E; Rahman, N; Banerjee, S (2016-06)
      The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA testing, such as ...
    • Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity. 

      Heindl, A; Khan, AM; Rodrigues, DN; Eason, K; Sadanandam, A; Orbegoso, C; Punta, M; Sottoriva, A; Lise, S; Banerjee, S; Yuan, Y (2018-09-25)
      How tumor microenvironmental forces shape plasticity of cancer cell morphology is poorly understood. Here, we conduct automated histology image and spatial statistical analyses in 514 high grade serous ovarian samples to ...
    • Nintedanib in ovarian cancer. 

      Khalique, S; Banerjee, S (2017-09)
      INTRODUCTION: Advanced ovarian cancer remains an unmet clinical need. Angiogenesis is considered a therapeutic target in ovarian cancer, with bevacizumab, a monoclonal antibody against VEGF, being the first drug to show a ...
    • Olaparib and somatic BRCA mutations. 

      George, A; Banerjee, S; Kaye, S (2017-07-04)
    • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. 

      Pujade-Lauraine, E; Ledermann, JA; Selle, F; Gebski, V; Penson, RT; Oza, AM; Korach, J; Huzarski, T; Poveda, A; Pignata, S; Friedlander, M; Colombo, N; Harter, P; Fujiwara, K; Ray-Coquard, I; Banerjee, S; Liu, J; Lowe, ES; Bloomfield, R; Pautier, P; SOLO2/ENGOT-Ov21 investigators (2017-09)
      BACKGROUND: Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade ...
    • Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. 

      Khalique, S; Naidoo, K; Attygalle, AD; Kriplani, D; Daley, F; Lowe, A; Campbell, J; Jones, T; Hubank, M; Fenwick, K; Matthews, N; Rust, AG; Lord, CJ; Banerjee, S; Natrajan, R (2018-07)
      ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ...
    • Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. 

      Oza, A; Kaye, S; Van Tornout, J; Sessa, C; Gore, M; Naumann, RW; Hirte, H; Colombo, N; Chen, J; Gorla, S; Poondru, S; Singh, M; Steinberg, J; Yuen, G; Banerjee, S (2018-05)
      BACKGROUND: Linsitinib, an oral, dual inhibitor of insulin-like growth factor-1 receptor and insulin receptor, in combination with weekly paclitaxel, may improve clinical outcomes compared with paclitaxel alone in patients ...
    • Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. 

      Friedlander, M; Banerjee, S; Mileshkin, L; Scott, C; Shannon, C; Goh, J (2016-12)
      Olaparib is the first oral poly(ADP-ribose) polymerase inhibitor to be approved as maintenance monotherapy for treatment of patients with platinum-sensitive relapsed BRCA-mutated (BRCAm) serous ovarian cancer. This review ...